IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

被引：49
|
作者：
Zhou, C. [1 ]
Das Thakur, M. [2 ]
Srivastava, M. K. [2 ]
Zou, W. [3 ]
Xu, H. [4 ]
Ballinger, M. [5 ]
Felip, E. [6 ]
Wakelee, H. [7 ]
Altorki, N. K. [8 ]
Reck, M. [9 ]
Liersch, R. [10 ]
Kryzhanivska, A. [11 ]
Harada, M. [12 ]
Tanaka, H. [13 ]
Hamm, J. [14 ]
McCune, S. [15 ]
McNally, V. [16 ]
Bennett, E. [5 ]
Gitlitz, B. [17 ]
Novello, S. [18 ]
机构：
[1] Tongji Univ, Dept Med Oncol, Affiliated Shanghai Pulm Hosp, Shanghai, Peoples R China
[2] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA
[3] Genentech Inc, Prod Dev Data Sci, San Francisco, CA 94080 USA
[4] F Hoffmann La Roche Ltd, Prod Dev Data Sci, Mississauga, ON, Canada
[5] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[6] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Oncol, Barcelona, Spain
[7] Stanford Univ, Sch Med, Med Oncol, Stanford Canc Inst, Stanford, CA 94305 USA
[8] NewYork Presbyterian Hosp, Weill Cornell Med, Cardiothorac Surg, New York, NY USA
[9] German Ctr Lung Res, Airway Res Ctr North, Lung Clin Grosshansdorf, Thorac Oncol, Grosshansdorf, Germany
[10] Clemenshosp Munster, Oncol, Munster, Germany
[11] Ivano Frankivsk Natl Med Univ, Gynecol Surg Dept, Ivano Frankivsk, Ukraine
[12] Hokkaido Canc Ctr, Resp Med, Sapporo, Hokkaido, Japan
[13] Niigata Canc Ctr Hosp, Dept Internal Med, Niigata, Japan
[14] Norton Canc Inst, Med Oncol, Louisville, KY USA
[15] Northwest Georgia Oncol Ctr, Res, Marietta, GA USA
[16] Roche Prod Ltd, Clin Dev, Welwyn Garden City, Herts, England
[17] Genentech Inc, Prod Dev, San Francisco, CA 94080 USA
[18] Univ Turin, Oncol, AOU San Luigi Gonzaga, Orbassano, Italy
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
20
引用
收藏
页码：S1374 / S1374
页数：1
相关论文
共 30 条
  • [1] IMpower010: Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Felip, E.
    Vallieres, E.
    Zhou, C.
    Wakelee, H.
    Bondarenko, I.
    Sakai, H.
    Saito, H.
    Ursol, G.
    Kawaguchi, K.
    Liu, Y.
    Levchenko, E.
    Kislov, N.
    Reck, M.
    Liersch, R.
    McNally, V. A.
    Zhu, Q.
    Ding, B.
    Bennett, E.
    Gitlitz, B.
    Altorki, N. K.
    ANNALS OF ONCOLOGY, 2021, 32 : S1319 - S1319
  • [2] IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
    Wang, Jie
    Fan, Yun
    Fang, Jian
    He, Jianxing
    Liu, Yunpeng
    Tao, Min
    Altorki, Nasser
    Felip, Enriqueta
    Wakelee, Heather
    Vallieres, Eric
    Belleli, Rossella
    McNally, Virginia
    Bennett, Elizabeth
    Gitlitz, Barbara J.
    Zhou, Caicun
    CANCER RESEARCH, 2024, 84 (07)
  • [3] IMpower010: A Phase III trial investigating atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy (chemo) in patients (pts) with completely resected NSCLC
    Zhou, C.
    Altorki, N.
    Vallieres, E.
    Felip, E.
    Zuo, Y.
    Howland, M.
    Xia, F.
    Hoang, T.
    Sandler, A.
    Wakelee, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] IMpower010: A Phase III Study of Atezolizumab vs Best Supportive Care Following Adjuvant Chemotherapy in Completely Resected NSCLC
    Felip, E.
    Wakelee, H.
    Vallieres, E.
    Zhou, C.
    Zuo, Y.
    Xia, F.
    Sandler, A.
    Altorki, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2398 - S2399
  • [5] IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Rittmeyer, Achim
    Reck, Martin
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Fu, Chenqi
    Ballinger, Marcus
    Deng, Yu
    Srivastava, Minu K.
    Bennett, Elizabeth
    Gitlitz, Barbara Jenifer
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8035 - LBA8035
  • [6] IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
    Wakelee, Heather
    Altorki, Nasser
    Vallieres, Eric
    Zhou, Caicun
    Zuo, Yunxia
    Howland, Michael
    Xia, Fan
    Hoang, Tien
    Sandler, Alan
    Felip, Enriqueta
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1305 - S1305
  • [7] IMpower010: Exploratory analysis of disease-free survival by KRAS status in patients with stage II-IIIA NSCLC treated with adjuvant atezolizumab vs best supportive care
    Reck, Martin
    Srivastava, Minu K.
    Wakelee, Heather A.
    Felip, Enriqueta
    Altorki, Nasser K.
    Csoszi, Tibor
    Moiseyenko, Vladimir
    Akopov, Andrey
    Smolin, Alexey
    Chella, Antonio
    Vallieres, Eric
    Martinez-Marti, Alex
    Zou, Wei
    McNally, V.
    Bennett, Elizabeth
    Prizant, Hen
    Nabet, Barzin
    Ballinger, Marcus
    Gitlitz, Barbara J.
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).
    Wakelee, Heather A.
    Altorki, Nasser K.
    Zhou, Caicun
    Csoszi, Tibor
    Vynnychenko, Ihor O.
    Goloborodko, Oleksandr
    Luft, Alexander
    Akopov, Andrey
    Martinez-Marti, Alex
    Kenmotsu, Hirotsugu
    Chen, Yuh-Min
    Chella, Antonio
    Sugawara, Shunichi
    Gitlitz, Barbara J.
    Bennett, Elizabeth
    Wu, Fan
    Yi, Jing
    Deng, Yu
    McCleland, Mark
    Felip, Enriqueta
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
    Vallieres, Eric
    Felip, Enriqueta
    Altorki, Nasser
    Zhou, Caicun
    Zuo, Yunxia
    Howland, Michael
    Xia, Fan
    Hoang, Tien
    Sandler, Alan
    Wakelee, Heather
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S304 - S304
  • [10] IMpower010: results from Asian patients in a phase 3 study of adjuvant atezolizumab in resected stage IB-IIIA NSCLC
    Kenmotsu, Hirotsugu
    Zhou, Caicun
    Altorki, Nasser
    Felip, Enriqueta
    Vallieres, Eric
    Sugawara, Shunichi
    Sakai, Hiroshi
    Saito, Haruhiro
    Tao, Min
    Kawaguchi, Koji
    Liu, Yunpeng
    Yu, Chong-Jen
    Wu, Qiong
    Lin, Huang
    Wu, Fan
    Bennett, Elizabeth
    Mcnally, Virginia
    Gitlitz, Barbara
    Wakelee, Heather
    ANNALS OF ONCOLOGY, 2022, 33 : S464 - S464
123